Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer - Takeaway - MDSpire
From the Journals

Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer

“Elinzanetant is the first approved targeted agent for [the vasomotor symptoms] that deeply affect the quality of life of breast cancer patients. By helping patients to tolerate better their breast ca...

Share

  • 1

    Elinzanetant reduces hot flashes and night sweats in breast cancer patients.

  • 2

    Presented by Dr. Fatima Cardoso at EBCC

  • 3

    Study involved patients aged 18 to 70 with breast cancer.

  • 4

    Therapy provides sustained relief regardless of hormone treatment type.

  • 5

    Most side effects were mild; common ones included diarrhea and fatigue.

  • 6

    Improved patient compliance may lead to better cancer outcomes.

  • 7

    Future research may explore interactions with other targeted agents.

Original Source(s)

Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer

  • by The ASCO Post Staff

  • April 13, 2026

Related Content

PSMA PET/CT Scan Reduces Need for Prostate Cancer Biopsies by 50%

A PSMA-11 PET/CT scan with gallium Ga-68 led to the identification of more aggressive prostate cancer cells in men with equivocal or nonsuspicious findings on multiparametric MRI than a standard biops...

Prompting Strategies May Improve Symptom Monitoring in Childhood Cancer Survivors

Prompting strategies on two large language models improved how the artificial intelligence (AI) interpreted pain and fatigue reported by survivors of childhood cancers for better symptom monitoring an...

FDA Fast-Tracks Off-the-Shelf CAR-T for Aggressive T-Cell Cancers

WashU Medicine-developed WU-CART-007 has received Breakthrough Therapy designation after early clinical results in relapsed or refractory T-cell leukemias and lymphomas.

  • April 14, 2026

  • 2 min